Researchers optimized drug target prioritization to increase odds of clinical trial success by integrating diverse human genetic data through a computational score. Credit: Lab of Ron Do, PhD.
Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score.
The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2].